Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[5][6] It contains doravirine, lamivudine, and tenofovir disoproxil.[7][6] It is taken by mouth.[5]
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[7][8]